Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

Exclusion Criteria11

• Subjects who meet any of the following criteria shall not be included in this study:
• Allergic to any drugs included in the trial protocol or drugs with a chemical structure similar to the investigational drug.
• Chemotherapy intolerance assessed by Ferrara 2013 criteria prior to enrollment.
• Hematologic relapse (bone marrow blasts or immature cells exceed 5%).
• Simultaneous diagnosis of other malignant tumors in organs (requiring treatment).
• Known or suspected drug abuse or alcohol dependence.
• Mental illness or any condition that prevents obtaining informed consent, or inability to comply with the study treatment and examination requirements.
• Liver dysfunction (total bilirubin \>1.5×ULN, ALT/AST \>2.5×ULN, or liver-involved patients with ALT/AST \>5×ULN), kidney dysfunction (serum creatinine \>1.5×ULN).
• Active heart disease, defined as one or more of the following:
• \) History of uncontrolled or symptomatic angina. 2) Myocardial infarction within 6 months prior to enrollment. 3) History of arrhythmias requiring drug treatment or with severe clinical symptoms.
• \) Uncontrolled or symptomatic congestive heart failure (\>NYHA class 2). 5) Ejection fraction below the lower limit of normal. 9.Participation in another clinical trial within 30 days. 10.Active infection. 11.The investigator deems the subject unfit for participation in this trial.